|
Match
|
Document |
Document Title |
|
|
US20090298866 |
Indole Compounds
The present application relates to compounds of formula (I) or a pharmaceutically acceptable derivative thereof: formula (I) wherein X, R 1 , R 2 , and R 3 are as defined in the specification, a...
|
|
|
US20090298832 |
TRISUBSTITUTED THIAZOLE COMPOUNDS, PREPARATIONS METHODS, PHARMACEUTICAL COMPOSITIONS AND MEDICALS USES THEREOF
The present invention relates to 2,4,5-trisubstituted thiazole compounds of formula (I) or all possible isomers, prodrugs, pharmaceutically acceptable salts, solvates or hydrates thereof for the...
|
|
|
US20090291936 |
OXIME DERIVATIVE AND PREPARATIONS THEREOF
The problem of the present invention is to provide a useful compound as a glucokinase activating agent, which is the oxime derivative of the formula [I]:
wherein Ring A is aryl or heteroaryl;
...
|
|
|
US20090281156 |
ENHANCING PHOTOSTABILIZATION OF OXYMETAZOLINE
The photostability of oxymetazoline in a topical decongestant composition is enhanced by lowering the pH of the composition using a buffer solution.
|
|
|
US20090281142 |
THIAZOLE DERIVATIVE
[Problem] To provide a compound which is useful as a GK activator. [Means for Resolution] As a result of an extensive study on thiazole derivatives, the present inventors have found that a...
|
|
|
US20090270456 |
Novel chemical compounds
This invention relates to newly identified compounds for inhibiting hYAK3 and/or CK2 proteins and methods for treating diseases associated with the imbalance or inappropriate activity of hYAK3...
|
|
|
US20090270445 |
Thiazole compounds and methods of use
The invention relates to methods of using thiazole compounds of Formula I and Formula II and compositions thereof for treating diseases mediated by protein kinase B (PKB) such as cancer and other...
|
|
|
US20090264484 |
Methods and Medicaments for Administration of Ibuprofen
A method for administration of ibuprofen to a subject in need of ibuprofen treatment is provided, in which an oral dosage form comprising a therapeutically effective amount of ibuprofen and a...
|
|
|
US20090258039 |
Method of administering a pharmaceutical active ingredient
A method for reducing the friability of soft substrates by applying an effective amount of a water soluble, polymeric dispersion to at least a portion of a treatment surface of the substrate, such...
|
|
|
US20090253705 |
HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS
The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of...
|
|
|
US20090247534 |
NEW COMPOUNDS
The present invention provides organic compounds of the following structure;
A-L1-B-C-D-L2-E
|
|
|
US20090239918 |
SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF
The invention provides methods for treating pain in mammals. In particular, the invention provides well-defined aminoimidazolines, aminothiazolines, and aminooxazolines and pharmaceutical...
|
|
|
US20090233970 |
COMBINED NSAID AND ACID BLOCKER FORMULATION AND METHOD
The present invention is directed to co-administration of a non-steroidal anti-inflammatory agent (NSAID) and acid blocking agent for the treatment of pain and inflammation with reduced...
|
|
|
US20090226500 |
SUTURES AND ANTI-SCARRING AGENTS
Sutures are used in combination with anti-scarring agents to inhibit fibrosis between the sutures and the host tissues into which the sutures are inserted. Compositions and methods are described...
|
|
|
US20090221574 |
5-Lipoxygenase-Activating Protein (FLAP) Inhibitors
Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods...
|
|
|
US20090215800 |
Enzyme and Receptor Modulation
Covalent conjugation of an alpha amino acid ester to a modulator of the activity of a target intracellular enzyme or receptor, wherein the ester group of the conjugate is hydrolysable by one or...
|
|
|
US20090203755 |
USE OF CRF1 RECEPTOR ANTAGONISTS FOR PREPARING A DRUG FOR TREATING METABOLIC SYNDROME AND/OR OBESITY AND/OR DYSLIPOPROTEINEMIA
An object of the present invention is the use of a compound of formula (I):
or one of its pharmaceutically acceptable salts,
for the manufacture of a medicament for the prevention and/or the...
|
|
|
US20090203754 |
ANTI-BACTERIAL DRUG TARGETING OF GENOME MAINTENANCE INTERFACES
Methods for the design and identification of novel antimicrobial compounds are provided, as well as antimicrobial compounds identified using these methods. Pharmaceutical compositions that include...
|
|
|
US20090203747 |
NOVEL CHEMICAL COMPOUNDS AND THE USES THEREOF AS A MEDICINE
The present invention relates to the field of pharmacy, especially the treatment of neurodegenerative diseases. The invention specifically relates to a family of chemical compounds for which a...
|
|
|
US20090203745 |
HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF
The present invention relates to compounds of formula (I) wherein: A is a radical selected from the group comprising aromatic heterocyclic 5-membered ring systems; Ar is a radical selected from the...
|
|
|
US20090203641 |
ANTIBIOTIC COMPOSITIONS AND RELATED SCREENING METHODS
Moenomycin inhibits bacterial growth by clocking the transglycosylase activity of class A penicillin-binding proteins (PBPs), which are key enzymes in bacterial cell wall synthesis. The binding...
|
|
|
US20090186895 |
ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical...
|
|
|
US20090182009 |
Compositions and methods of treating retinal disease
Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for...
|
|
|
US20090176756 |
SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS
The present invention relates to substituted thiazoles, to methods for the production thereof, to medicaments containing these compounds and to the use thereof for producing medicaments.
|
|
|
US20090170842 |
BRCA1-BASED BREAST OR OVARIAN CANCER PREVENTION AGENTS AND METHODS OF USE
A pharmaceutical composition for use in treating, inhibiting, and/or preventing breast and/or ovarian cancer can include: a molecule having a structure of one of Compounds 1-38, pharmaceutically...
|
|
|
US20090156611 |
MAMMALIAN HEDGEHOG SIGNALING MODULATORS
The disclosure relates to compositions for and methods of inhibiting the mammalian Hedgehog signaling pathway.
|
|
|
US20090143447 |
Seed Treatment Formulations and Methods of Use
The present invention generally relates to aqueous seed treatment formulations comprising a pesticidal agent, a polyvinyl alcohol (PVA), a graft copolymer, and a plasticizer. In one embodiment of...
|
|
|
US20090142393 |
Stable Compositions of Famotidine and Ibuprofen
Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface...
|
|
|
US20090137645 |
Shelf-Stable Famotidine Granulates for Oral Suspensions
A granulate for oral suspension that is particularly useful for the storage and reconstitution of famotidine into a liquid suspension.
|
|
|
US20090131462 |
Fungicidally Active Agent
The invention relates to a fungicidally active agent containing at least one other defined fungicide in addition to the fungicide...
|
|
|
US20090131439 |
Therapeutic agent for chronic obstructive pulmonary disease
Disclosed is a method for the prevention and/or treatment of a chronic obstructive pulmonary disease by administrating a 5-membered cyclic compound represented by the formula below:
or a...
|
|
|
US20090093529 |
REMEDY FOR OVERACTIVE BLADDER COMPRISING ACETIC ACID ANILIDE DERIVATIVE AS THE ACTIVE INGREDIENT
(R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethy
l)amino]ethyl]acetic acid anilide or its salt shows a potent bladder relaxation effect in “isolated rat bladder smooth muscle...
|
|
|
US20090093527 |
Azacyclopentane Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase
Azacyclopentane derivatives of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The...
|
|
|
US20090093452 |
Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives
Disclosed are compounds and pharmaceutically acceptable salts of Formula I
wherein R Q , R 7 , n, Q 2 , Q 3 , Y, and X 1 -X 3 are as defined herein. Compounds of Formula I are useful in the...
|
|
|
US20090088432 |
Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors
The present invention encompasses; the novel substituted heterocyclic compounds represented by formula (I) or their pharmaceutically acceptable salts, wherein the substituents in formula (I) have...
|
|
|
US20090069395 |
DEUTERIUM-ENRICHED FAMOTIDINE
The present application describes deuterium-enriched famotidine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
|
|
|
US20090048270 |
Compounds, Methods And Devices for Inhibiting Neoproliferative Changes in Blood Vessel Walls
Methods, compositions and devices for inhibiting neoproliferative changes in blood vessel walls or other anatomical structures. One or more compounds of Formula I or I-A set forth herein are...
|
|
|
US20090048248 |
Octahydropyrano[3,4-C]Pyrrole Tachykinin Receptor Antagonists
The present invention is directed to certain hydropyranopyrrolidine compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance...
|
|
|
US20090041863 |
Use of GSK3 inhibitors in combination with radiation therapies
The presently disclosed subject matter relates generally to the fields of molecular biology and medicine. More particularly, it concerns methods involving the use of GSK3 inhibitors in combination...
|
|
|
US20090023740 |
SODIUM CHANNEL INHIBITORS
Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-gated sodium channels. More particularly,...
|
|
|
US20090018056 |
Heteroarylcarbamoylbenzene derivatives
Compounds having glucokinase activating effects and being useful as treatments for diabetes, which are represented by the following formula (I):
[wherein X 1 represents oxygen, etc., X 2 ...
|
|
|
US20090012117 |
Bicyclic derivatives as modulators of ion channels
Bicyclic derivatives having formula (I) and a composition thereof are useful as ion channel antagonists:
|
|
|
US20090012093 |
Receptor Function Regulator
The GPR40 receptor function regulator of the present invention, which comprises a compound having an aromatic ring and a group capable of releasing cation is useful as an insulin secretagogue or an...
|
|
|
US20090005568 |
Substituted 2-aminothiazoles for treating neurodegenerative diseases
The invention relates to substituted 2-aminothiazole derivatives useful in treating disorders that are mediated by A 2a receptor function, including neurodegenerative diseases including...
|
|
|
US20080312223 |
Thiazole And Isothiazole Derivatives That Modulate The Activity Of CDK, GSK And Aurora Kinases
The invention provides a compound of the formula (I): or a salt, N-oxide, tautomer or solvate thereof, wherein X is CR 5 or N; each of Q 1 and Q 2 is a carbon atom; Q 3 is selected from S and...
|
|
|
US20080312184 |
Composition for Preventing Plant Diseases and Method for Preventing the Diseases
The present invention is to provide a composition for preventing plant diseases which comprises at least Component I and Component II, is capable of obtaining a synergic effect that cannot be...
|
|
|
US20080300285 |
Chemical Compounds
The use of a compound of formula (I) wherein X is (i), (ii) or (iii), formula (i), formula (ii), formula (iii) Y is O, S(O) m , NR 3 , CR 5 R 6 , CR 5 R 6 —CR 7 R 8 , O—CR 7 R 8 , S(O) m —CR...
|
|
|
US20080300266 |
1-(Hetero)Aryl-3-Amino-Pyrrolidine Derivatives for Use as Mglur3 Antagonists
The present invention relates to compounds of the Formula (I) which are useful for treating conditions associated with mGluR3 receptors, such as depression, schizophrenia and migraine,...
|
|
|
US20080293786 |
NOVEL 2-IMINO-1,3-THIAZOLINE-BASED COMPOUNDS AND T-TYPE CALCIUM CHANNEL INHIBITORS CONTAINING THE SAME
Novel 2-imino-1,3-thiazoline based compounds represented by Chemical Formula I, and T-type calcium channel inhibitors containing the compound are provided. The T-type calcium channel inhibitors...
|
|
|
US20080293569 |
Indanyl- and Tetrahydronaphthyl-Amino-Azoline Compounds for Combating Animal Pests
The present invention relates to Indanyl- and Tetrahydronaphthyl-amino-azoline compounds of formula I
wherein the variables R 1 and R 2 are as defined in description. The invention relates...
|